Throughout the world, new or novel excipients are only approved within new drug applications, and there is no independent regulatory approval process for new excipients.
IPEC-Americas (International Pharmaceutical Excipients Council) and the Coalition for the Monitoring of Melamine Contamination (CHPA, GPhA, IPEC, PhRMA, SOCMA) has partnered with RX-360
